8-K: Indaptus Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics reported its second quarter 2024 financial results, highlighted clinical trial progress, and announced a recent $3 million capital raise.

Summary

• Indaptus Therapeutics, a clinical-stage biotech company, released its financial results for the second quarter ending June 30, 2024.
• The company's research and development expenses were approximately $1.7 million for the quarter, an increase of $0.2 million compared to the same period in 2023.
• General and administrative expenses for the quarter were approximately $2.4 million, up $0.4 million year-over-year.
• The loss per share for the quarter was $0.47, compared to $0.39 in the second quarter of 2023.
• For the six months ended June 30, 2024, research and development expenses were approximately $3.3 million, a decrease of $0.1 million compared to the same period in 2023.
• General and administrative expenses for the six months were approximately $4.7 million, an increase of $0.1 million year-over-year.
• The loss per share for the six months was $0.92, compared to $0.89 for the same period in 2023.
• As of June 30, 2024, the company had approximately $7.3 million in cash and cash equivalents.
• On August 8, 2024, Indaptus completed a $3 million registered direct offering and concurrent private placement, resulting in net proceeds of approximately $2.5 million.
• The company expects its current cash to fund operations into the first quarter of 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company is making progress in its clinical trials and has secured additional funding, the increased losses and decreased cash position are concerning. The company's future is dependent on the success of its clinical trials and its ability to secure additional funding.

Positives

• The company successfully raised $2.5 million in net proceeds through a registered direct offering and private placement.
• The Phase 1 clinical trial of Decoy20 is progressing with the transition to weekly dosing.
• The company presented data at major oncology conferences, increasing visibility.
• The company's founder was recognized as chair of a key industry summit.
• Net cash used in operating activities decreased by approximately $0.7 million for the six months ended June 30, 2024, compared to the same period in 2023.

Negatives

• The company experienced an increased loss per share for both the three and six months ended June 30, 2024, compared to the same periods in 2023.
• Research and development expenses increased for the three months ended June 30, 2024.
• General and administrative expenses increased for both the three and six months ended June 30, 2024.
• The company's cash and cash equivalents decreased from $13.4 million at the end of 2023 to $7.3 million as of June 30, 2024.

Risks

• The company has a limited operating history and may face challenges in achieving profitability.
• The company's clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome.
• The company relies on third parties for clinical trials and manufacturing, which could introduce risks.
• The company's ability to obtain regulatory approval and market acceptance for its product candidates is uncertain.
• The company may need to raise additional capital to fund its operations beyond the first quarter of 2025.
• The company faces competition from other biotechnology companies.

Future Outlook

The company expects its current cash and cash equivalents to support its ongoing operating activities into the first quarter of 2025, based on current operational plans and excluding any additional funding or business development activities.

Management Comments

• Jeffrey Meckler, Indaptus Therapeutics Chief Executive Officer, stated that they had multiple opportunities to share findings regarding their Phase 1 clinical trial and demonstrate the unique approach of their Decoy platform.
• He also mentioned that they are encouraged by the results reported and the data they are seeing as they continue the multi-dose stage of the Phase 1 clinical trial.
• The CEO noted that they expect to progress to dosing multiple patients simultaneously, which is expected to accelerate the progress of the trial.
• The CEO stated that they look forward to demonstrating continued impactful outcomes in the second half of the year.

Industry Context

This announcement comes as the biotechnology industry continues to focus on innovative cancer and viral infection treatments, with a particular emphasis on immunotherapy approaches. Indaptus's Decoy platform, which targets multiple immune receptors, aligns with the industry's trend towards multi-targeted therapies.

Comparison to Industry Standards

• Indaptus's research and development expenses of $1.7 million for the quarter are relatively low compared to larger, more established biotech companies in clinical trials, such as companies like Iovance Biotherapeutics or Adaptimmune, which often spend tens of millions per quarter.
• The company's cash position of $7.3 million is also modest compared to companies with similar clinical programs, which often have cash reserves in the tens or hundreds of millions.
• The $2.5 million capital raise is small compared to the typical funding rounds of clinical-stage biotech companies, which often raise tens or hundreds of millions of dollars.
• The company's focus on a novel platform technology is similar to other early-stage biotech companies, but the specific approach of using attenuated bacteria to activate multiple immune receptors is unique.
• The company's clinical trial progress, moving from single to weekly dosing, is a typical step in early-stage clinical development, similar to other companies in Phase 1 trials.

Stakeholder Impact

• Shareholders may be concerned about the increased losses and decreased cash position.
• Employees may be impacted by the company's financial situation and future funding needs.
• Customers and partners may be interested in the progress of the clinical trials and the potential of the Decoy platform.
• Creditors may be monitoring the company's financial health and ability to meet its obligations.

Next Steps

• The company plans to initiate weekly dosing of Decoy20 in multiple patients.
• Indaptus will continue to assess all financing options to support its corporate strategy.
• The company will continue its Phase 1 clinical trial of Decoy20.
• The company will file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 with the SEC.

Key Dates

Keywords

biotechnology, clinical trial, Decoy20, cancer, immunotherapy, financial results, capital raise, research and development, oncology, Phase 1